BeOne Medicines AG (HKG:6160)
Hong Kong · Delayed Price · Currency is HKD 251.80
-0.40 (-0.16%)
Nov 11, 2026, 4:08 PM HKT
BeOne Medicines AG Stock Forecast
Stock Price Forecast
According to 16 analysts polled by S&P Global, BeOne Medicines AG stock has a consensus rating of "Strong Buy" and an average price target of $278.67. The average 1-year stock price forecast is 10.67% higher than the current stock price, while the lowest is $226.94 (-9.87%) and the highest is $337.01 (+33.84%).
Price Target: $278.67 (+10.67%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for BeOne Medicines AG stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 13 | 14 | 13 | 12 | 12 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 18 | 17 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Daiwa No rating | Daiwa | Buy Maintains $270.00 → $286.00 | Buy | Maintains | $270.00 → $286.00 | +13.58% | Nov 11, 2026 |
Unknown Analyst CLSA No rating | CLSA | Buy Maintains $336.80 | Buy | Maintains | $336.80 | +33.76% | Nov 10, 2026 |
Unknown Analyst CICC No rating | CICC | Buy Maintains $266.00 → $281.00 | Buy | Maintains | $266.00 → $281.00 | +11.60% | Nov 7, 2026 |
Unknown Analyst UBS No rating | UBS | Buy Maintains $280.20 → $529.00 | Buy | Maintains | $280.20 → $529.00 | +110.09% | Nov 5, 2026 |
| DBS | DBS | Buy Maintains $290.00 | Buy | Maintains | $290.00 | +15.17% | Sep 28, 2026 |
Financial Forecast
Revenue This Year
6.90B
from 5.34B
Increased by 29.05%
Revenue Next Year
7.93B
from 6.90B
Increased by 15.06%
EPS This Year
0.80
from 0.19
Increased by 319.67%
EPS Next Year
1.04
from 0.80
Increased by 30.41%
EPS and Forward PE are based on non-GAAP adjusted numbers.